![](https://investorshub.advfn.com/uicon/40536.png?cb=1561902029)
Saturday, May 11, 2019 12:00:28 PM
Now the hematopoietic, mesenchymal and endothelial progenitor cells present in the patient's bone marrow take on a leading role in the treatment of erectile dysfunction. Erectile dysfunction is a condition closely related to age, psychological, neurological and hormonal factors. It has an extremely significant impact on the quality of life of the patient and therefore reflected in the social fabric. Epidemiological data in Italy place the problem, in terms of prevalence, among those most frequently encountered. Currently around 3 million men are affected by erectile dysfunction, but it is estimated that they could be at least twice as many. In the field of biomedical research, regenerative medicine has successfully established itself over the last decade through the development of new strategies and alternative treatments to conventional therapies, using growth factors and other intercellular signals capable of stimulating the natural healing process of the human body. The hematopoietic, mesenchymal and endothelial progenitor cells used in the patient's bone marrow are used. The administration of stem cells directly into the penis can reverse the pathophysiological changes that lead to erectile dysfunction, in addition to treating the symptoms effectively. In about 15 minutes, a small amount of autologous material from the iliac crest is extracted from the patient, and obtains a concentrated cellular product which is injected into the corpus cavernosum of the penis of the patient himself. The CaverStem * procedure, scientifically already validated in the USA, allows a safe, fast and free of side effects sampling to be performed on an outpatient basis. In Rome the only authorized European center for this treatment.
Just three months after implantation, an increase in the duration and frequency of the erection was detected, in addition to maintaining it until reaching orgasm.
Side effects are virtually absent and no post-procedure complication has occurred. Some patients have even been treated with a double stem cell and Prp graft, with truly exceptional results in terms of resumption of sexual activity that allow us to glimpse a truly rosy future for the non-invasive and non-surgical treatment of erectile dysfunction.
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM